by Anne Staylor and Mary Thompson
For device developers, the market for acute ischemic stroke (AIS) has been enticing as the lack of effective treatment options coupled with the huge unmet clinical need and growing patient population seems to be a good target for technological innovation. However, developing an effective treatment for AIS is not an easy task, and many companies have found the road forward to be a bumpy one. Brain cells begin to die of oxygen deprivation within three to four minutes of AIS onset and treatment options are limited by how quickly patients seek help
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?